Skip to main content
SpringerLink
Log in

Lower price for valganciclovir in developing countries

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Backed by the United Nations, the Medicines Patent Pool aims to lower the prices of HIV drugs by creating a pool of relevant patents for licensing to generic manufacturers and other producers, facilitating generic competition that brings down prices.

Reference

  • Roche, et al. Roche and the Medicines Patent Pool Sign Agreement to Increase Access to Medicines to Treat CMV infection in HIV-patients, a major cause of Blindness. Media Release : 5 Aug 2013. Available from: URL: http://www.roche.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lower price for valganciclovir in developing countries. PharmacoEcon Outcomes News 684, 11 (2013). https://doi.org/10.1007/s40274-013-0627-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0627-8

Search

Navigation